suggested remit: To appraise the clinical and cost effectiveness of burosumab within its marketing authorisation for treating X-linked hypophosphatemia (XLH) in adults
Status Awaiting development
Decision None selected
Process STA 2018
ID number 3822

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
09 December 2021 The topic was discussed at the Topic Selection Oversight Panel (TSOP) in October 2021. The panel concluded that the topic was suitable for a Technology Appraisal. Following conversations with the company, the scheduling of the evaluation is to be confirmed and stakeholders will be updated in due course.
04 March 2021 (10:00) Scoping workshop
07 January 2021 - 04 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual